Crumlin, England (ots/PRNewswire) – Hochsensible & -spezifische Biomarker myokardialer Ischämie können nun routinemässig für die Diagnose des akuten Koronarsyndroms (Acute Coronary Syndrome, ACS) verwendet werden. Das internationale klinische Diagnostikunternehmen Randox Laboratories hat heute einen automatisierten Laborassay für Herz-Fettsäure-bindendes Protein (H-FABP) lanciert, der die Diagnose und das Management von Patienten mit vermutetem akuten Koronarsyndrom (Acute Coronary [...]
Tag Archive > Acute Coronary Syndrome
Phase II Study Showed Switching ACS-PCI patients on maintenance clopidogrel/aspirin to prasugrel/aspirin reduced maximal platelet aggregation after one week
Indianapolis and Tokyo (ots/PRNewswire) – In a Phase II study, Acute Coronary Syndrome (ACS) patients on maintenance clopidogrel/aspirin therapy who were switched to prasugrel (Efient(R) – either 10 mg maintenance dose [MD] or 60 mg loading dose [LD] followed by 10 mg MD) plus aspirin demonstrated a statistically significant greater reduction in Maximal Platelet Aggregation [...]
Largest Atrial Fibrillation Registry Reveals Poor AF Control and High Rates of Cardiovascular Hospitalization
Paris (ots/PRNewswire) – Sanofi-aventis announced today that results from the RealiseAF (Real-life global survey evaluating patients with Atrial Fibrillation) registry show that control of atrial fibrillation (AF) (defined by the 2006 ACC/AHA/ESC AF guidelines as either sinus rhythm or AF with heart rate at rest less than or equal 80 bpm)[1] was not achieved in [...]
Resverlogix Scientific Data Presented at EAS Congress
Hamburg and Calgary, Canada, June 22, 2010 (ots/PRNewswire) – Resverlogix Corp. (“Resverlogix” or the “Company”) announced today that key scientific data was communicated in an oral presentation highlighting the novel features of the Company’s lead drug RVX-208 at the European Atherosclerosis Society Congress (EAS) conference being held in Hamburg, Germany. The presentation titled “RVX-208 given [...]
New Analysis Showed Efient(R) Cost-Effective Compared with Clopidogrel for Patients with Acute Coronary Syndromes Undergoing PCI
Tokyo and Indianapolis (ots/PRNewswire) – Results from a health economic substudy of the TRITON-TIMI 38 clinical trial showed that among patients with acute coronary syndrome (ACS) managed with percutaneous coronary intervention (PCI), including stenting, treatment with Efient(R) (prasugrel) compared with branded clopidogrel (Plavix(R)) was more cost effective, and in most cases cost saving. These results [...]
Resverlogix Commences Phase 2 Atherosclerosis Clinical Trial
Calgary, Canada (ots/PRNewswire) – Resverlogix Corp. (“Resverlogix” or the “Company”) announced today that it has begun dosing patients in its US Phase 2 clinical trial lead by Cleveland Clinic. This trial will examine RVX-208, Resverlogix’s oral small molecule therapy for the treatment of atherosclerosis, in patients with stable coronary artery disease (CAD). This study is [...]
Three European Analyses Showed Efient is Cost-Effective Compared with Clopidogrel in Patients with Acute Coronary Syndrome Undergoing PCI
Paris (ots/PRNewswire) – Results from three separate European health economic analyses of the TRITON-TIMI 38 study showed that treatment with Efient(R) (prasugrel) compared with clopidogrel (Plavix(R)) reduced medical costs by lowering rehospitalisation rates and the need for repeat percutaneous coronary interventions (PCI), including stenting. The analyses, conducted in Germany, France and the UK, showed prasugrel [...]
Resverlogix Notice of Conference Call & Webcast to Discuss Clinical Trial Data
Calgary, Canada (ots/PRNewswire) – Resverlogix Corp. (TSX:RVX) announced today that it will host a live teleconference and webcast on Tuesday, September 29, 2009 at 1:00 pm Eastern/11:00 am Mountain time. The purpose of the teleconference is to discuss the top line results of the Company’s Phase 1b/2a clinical trial for RVX-208, an oral small molecule [...]
Study Shows Otamixaban Substantially Reduced Complications of Invasive Management of Acute Coronary Syndromes
Paris (ots/PRNewswire) – – SEPIA-ACS Multiple-dose Phase II Results Showing 27- 42% Risk Reduction in ACS Complications Presented in Plenary Session of European Society of Cardiology Congress and Published in The Lancet Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that the investigational anti-Xa intravenous anticoagulant otamixaban reduced by 27 to 42 percent the odds [...]
New Large-Scale, Global Study Provides Additional Information About an Intensified Dose-Regimen of PLAVIX(R) in Acute Coronary Syndrome Patients Undergoing Angioplasty
Paris, and Princeton, New Jersey (ots/PRNewswire) – -No added benefit on the composite primary end-point with the higher dose when entire ACS study population considered- -Important new findings with higher loading dose of PLAVIX(R) for heart patients undergoing coronary angioplasty (PCI)- Today, the OASIS study group will present initial results of the CURRENT-OASIS 7 clinical [...]
World Heart Federation, Daiichi Sankyo and Lilly Partner to Improve Cardiovascular Health
Orlando, Florida (ots/PRNewswire) – The World Heart Federation, Daiichi Sankyo Company, Limited (TSE: 4568) and Eli Lilly and Company (NYSE: LLY) announced today that they have partnered to improve cardiovascular health internationally. The organizations made the announcement at the 58th Annual Scientific Session of the American College of Cardiology in Orlando, Florida. An estimated 17.5 [...]
Richter-Helm and Athera Biotechnologies Partner in Development of Recombinant Protein to Treat Cardiovascular Disease
(pressebox) Hamburg, Germany and Stockholm, Sweden, 21.01.2009, Richter-Helm BioLogics GmbH & Co. KG and Athera Biotechnologies AB have signed an agreement for the development and manufacturing of Athera?s novel product for prevention of plaque rupture and athero-thrombosis through binding of the protein, Annexin A5, to endothelium. The recombinant protein Annexin A5 is intended for the [...]
